alleigic rhinitis
Conditions
Interventions
real catgut implantation at acupoints group:catgut implantation at acupoints
controlled group:sham catgut implantation at acupoints
Sponsors
Teaching Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: According to ARIA (2008 Update), the diagnostic criteria for allergic rhinitis is based upon the coordination between a typical history of allergic symptoms and diagnostic tests. They are: 1. Typical symptoms of allergic rhinitis: rhinorrhoea, sneezing, nasal obstruction and pruritus. Some patients may have ocular symptoms for outdoor allergens. 2. Prick and puncture tests performed by trained health professionals. 3. The blood specific IgE. The time when subjects have above symptoms should last more than one hour on most days. Standardized vaccines (Alutard SQ, ALK- Abelló, Denmark) are used in the test. Oral H1-antihistamines are not permitted before skin test. And skin tests should be read at the peak of their reaction by measuring the wheal and the flare approximately 15 min after the performance of the test.1 Patients who meet the diagnosis of allergic rhinitis will be included in this study. The criteria are: (1) aged between 18-70 years; (2) not be taking part in any other clinical trials; (3) having no previous experience of catgut implantation at acupoints; (4) provide written informed consent.
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions will be excluded: (1) pregnant women or women who are ready to be pregnant in recent half year, women with lactation; (2) patients are receiving immune therapy; (3) patients with other allergic diseases, such as bronchial asthma or allergic purpura; (4) patients with nasal polyposis; (5) heterologous protein allergy; (6) patients with other organic disorders, such as: AIDS, vascular malformation, hypertension, hematologic diseases, diabetes mellitus, malignant tumor, mental disorder; (7) patients with previous experiences of catgut implantation at acupoints; (8) patients who are unwilling to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analog scale for the measurement of severity;SF-36 questionaire of QOL;serum allergen-specific IgE;nasal inflammatory cells counts(mast cells, eosinophils, basophils); | — |
Secondary
| Measure | Time frame |
|---|---|
| relief medication score; | — |
Countries
China
Contacts
Public ContactZHANG Qin-xiu
Outcome results
None listed